Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:38:32 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:OLMA - OLEMA PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
OLMA - Q0.19.21·10.808.29.93+0.030.3741.16,9115,9559.67  10.16  9.3517.7911  3.6416:04:47Apr 0815 min RT 2¢

Recent Trades - Last 10 of 5955
Time ETExPriceChangeVolume
16:04:47Q9.930.037,100
16:04:46Q9.930.031,036
16:04:45Q9.930.0393
16:04:43Q9.930.0314,409
16:04:36Q9.930.03692
16:04:32Q9.930.03201
16:04:30Q9.930.03374
16:04:29Q9.930.03200
16:04:19Q9.930.031,314
16:04:08Q9.930.0316,505

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-08 16:30U:OLMANews ReleaseOlema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
2024-04-02 16:29U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-11 16:03U:OLMANews ReleaseOlema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
2024-03-06 07:03U:OLMANews ReleaseOlema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
2024-03-04 16:30U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-06 07:01U:OLMANews ReleaseOlema Oncology to Participate in Upcoming Investor Conferences
2024-02-02 16:30U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 08:13U:OLMANews ReleaseOlema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
2024-01-02 16:01U:OLMANews ReleaseOlema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-05 12:28U:OLMANews ReleaseOlema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
2023-12-04 16:29U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-28 17:10U:OLMANews ReleaseOlema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
2023-11-07 16:02U:OLMANews ReleaseOlema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-02 16:32U:OLMANews ReleaseOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-01 16:27U:OLMANews ReleaseOlema Oncology to Participate in Upcoming Investor Conferences in November
2023-10-22 02:55U:OLMANews ReleaseOlema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
2023-10-17 07:01U:OLMANews ReleaseOlema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
2023-10-16 07:02U:OLMANews ReleaseOlema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
2023-10-12 07:01U:OLMANews ReleaseOlema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
2023-10-10 07:00U:OLMANews ReleaseOlema Oncology Announces Expansion of Collaboration Agreement with Novartis